2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 Ịdị ọcha ≥98.0% Olaparib Intermediate Factory
Ịdị ọcha dị elu, mmepụta azụmahịa
Olaparib na ndị etiti emetụtara:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid CAS 763114-26-7
1- (Cyclopropylcarbonyl) piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Aha Chemical | 2-Fluoro-5-Formylbenzonitrile |
| Ụdị okwu | 3-Cyano-4-Fluorobenzaldehyde |
| Nọmba CAS | 218301-22-5 |
| Nọmba CAT | RF-PI451 |
| Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
| Usoro ihe omimi | C8H4FNO |
| Ibu molekụla | 149.12 |
| Ebe Na-agbaze | 80.0 ruo 84.0 ℃ (ọkụ) |
| Solubility | Soluble na methanol |
| Ụdị | Ruifu Chemical |
| Ihe | Nkọwapụta |
| Ọdịdị | Yellow ruo Gbanyụọ-ọcha ntụ ntụ |
| Ịdị ọcha | ≥98.0% |
| Mmiri (KF) | ≤0.50% |
| Mgbakọta adịghị ọcha | ≤2.0% |
| Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
| Ojiji | Ọkara nke Olaparib (CAS: 763113-22-0) PARP-Inhibitor |
ngwugwu: Kalama, Aluminom foil bag, Cardboard Drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri.
2-Fluoro-5-Formylbenzonitrile (CAS: 218301-22-5) na-eji na nkwadebe nke heterocyclic ogige dị ka PARP inhibitors maka ọgwụ.A na-eji 2-Fluoro-5-Formylbenzonitrile mee ihe dị ka etiti nke Olaparib (CAS: 763113-22-0).Olaparib bụ obere ihe mgbochi molecule nke PARP1/PARP2 (IC50: 5/1 nM) mana ọ naghị adị irè megide PARP tankyrase-1 (IC50: 1.5 µM).Olaparib (AZD-2281, aha ahia Lynparza) bụ ọgwụgwọ ezubere iche nke FDA kwadoro maka ọrịa kansa, nke KuDOS Pharmaceuticals mepụtara ma mesịa site na AstraZeneca.Ọ bụ ihe mgbochi PARP, na-egbochi poly ADP ribose polymerase (PARP), enzyme na-etinye aka na nrụzi DNA. Ọ na-eme megide ọrịa cancer na ndị nwere mmụgharị BRCA1 ma ọ bụ BRCA2 nketa, nke gụnyere ụfọdụ ọrịa ovarian, ara na prostate.Na Disemba 2014, EMA na FDA kwadoro olaparib ka ọ bụrụ otu onye nnọchi anya.Nkwenye FDA dị maka germline BRCA mutated (gBRCAm) ọrịa cancer ovarian dị elu nke natara ahịrị atọ ma ọ bụ karịa tupu usoro ọgwụgwọ chemotherapy.
